Generalized Anxiety Disorder Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | VistaGen Therapeutics, MindMed, Sumitomo Pharma America, Inc., Otsuka Pharmaceutical Co., Ltd, Sunovion Pharmaceuticals Inc.,

DelveInsight's " Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Generalized Anxiety Disorder, historical and forecasted epidemiology as well as the Generalized Anxiety Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Generalized Anxiety Disorder Market Share @ Generalized Anxiety Disorder Market Outlook- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Generalized Anxiety Disorder Market Research Report
• In March 2025, Otsuka Pharmaceuticals announced a clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
• In March 2025, Mind Medicine Inc. announced a study will enroll up to 375 participants aged 18 to 74 years, inclusive with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) confirmed primary diagnosis of GAD and a minimum HAM A total score of at least 20 at Screening and Baseline without clinically relevant medical or psychiatric history.
• The overall count of individuals diagnosed with GAD in the United States was approximately 8,770 thousand in 2023, and these numbers are expected to increase at an estimated CAGR throughout the study period (2020-2034).
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of GAD, with 1,460 thousand cases, followed by Italy and Spain in 2023. On the other hand, the UK had the lowest prevalent population in the European region in 2023.
• In 2023, Japan reported approximately 1,360 thousand diagnosed prevalent cases of GAD.
• Gender-specific diagnosed prevalent cases of GAD showed that females were more affected by GAD than males in the 7MM.
• As per DelveInsight's analysis, the diagnosed prevalent cases of GAD based on age were categorized into four groups: 18-29 years, 30-44 years, 45-59 years, and 60 years and above. The highest proportion of GAD cases was estimated in the 45-59 years age group in the 7MM, while the least cases were in the age group 18-29 years.
• The cases of GAD were classified based on severity levels, into mild, moderate, and severe categories. DelveInsight's estimations reveal that the highest number of severity-specific cases in the US was attributed to moderate cases, totaling 3,910 thousand, in 2023.
• The leading Generalized Anxiety Disorder Companies such as VistaGen Therapeutics, MindMed, Sumitomo Pharma America, Inc., Otsuka Pharmaceutical Co., Ltd, Sunovion Pharmaceuticals Inc., Cybin IRL Limited, Engrail Therapeutics Inc., Bionomics Limited, Receptor Life Sciences, MannKind Corporation, and others
• Promising Generalized Anxiety Disorder Pipeline Therapies such as MM-120, PH94B, Vilazodone (Viibryd), Intuniv (Guanfacine), BNC210, and others.

Discover which therapies are expected to grab the Generalized Anxiety Disorder market share @ Generalized Anxiety Disorder Market Outlook- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Generalized Anxiety Disorder Epidemiology Segmentation in the 7MM
• Generalized Anxiety Disorder Diagnosed Prevalent Cases
• Generalized Anxiety Disorder Age-specific Diagnosed Prevalent Cases
• Generalized Anxiety Disorder Gender-specific Diagnosed Prevalent Cases
• Generalized Anxiety Disorder Severity-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Generalized Anxiety Disorder epidemiology trends @ Generalized Anxiety Disorder Prevalence- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Generalized Anxiety Disorder Emerging Drugs
• Fasedienol (PH94B): VistaGen Therapeutics
PH94B presents a promising advancement in the Generalized Anxiety Disorder pipeline and is currently in Phase III, characterized by its rapid onset, sustained therapeutic effect, and the convenience of a single administration. These attributes not only address the critical need for quicker relief in anxiety disorders but also enhance patient compliance. The unique profile of PH94B, combined with its potential to offer a durable response with minimal dosing, positions it as a valuable innovation in the treatment landscape for GAD. These factors underscores the compound's potential to redefine standards in anxiety disorder management, potentially providing a more efficient and patient-friendly alternative for individuals grappling with GAD.

• MM-120 (LSD D-Tartrate): MindMed
MM-120 (LSD D-Tartrate) is under clinical development by Mind Medicine, Inc. and is currently in Phase II for Generalized Anxiety Disorder treatment. Administered orally, it is a pharmacologically enhanced version of lysergic acid diethylamide (LSD). This candidate has promising and enduring benefits against symptoms of anxiety and depression.

Generalized Anxiety Disorder Drugs Market Insights
Generalized Anxiety Disorder market lacks universally effective, fast-acting treatments with minimal side effects. This underscores the necessity for personalized, safer, and more accessible therapies to enhance outcomes for individuals with GAD. Nevertheless, the emerging pipeline for GAD treatments is not highly competitive, with few companies showing interest in developing therapies for this condition.

To learn more about Generalized Anxiety Disorder treatment guidelines, visit @ Generalized Anxiety Disorder Treatment Market Landscape- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Generalized Anxiety Disorder Companies
VistaGen Therapeutics, MindMed, Sumitomo Pharma America, Inc., Otsuka Pharmaceutical Co., Ltd, Sunovion Pharmaceuticals Inc., Cybin IRL Limited, Engrail Therapeutics Inc., Bionomics Limited, Receptor Life Sciences, MannKind Corporation, and others

Generalized Anxiety Disorder Treatment Landscape
The primary treatment goal in GAD is to alleviate excessive, persistent worry and anxiety and to improve overall functioning and well-being. The standard array of pharmacological agents employed in the management of GAD encompasses a diverse range, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), antiepileptics like pregabalin, tricyclic antidepressants(TCAs) that impact mood regulation, benzodiazepines offering rapid relief, antihistamines, atypical antipsychotics, and antioxidants

Learn more about the FDA-approved drugs for Generalized Anxiety Disorder @ Drugs for Generalized Anxiety Disorder Treatment- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Generalized Anxiety Disorder Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Generalized Anxiety Disorder Companies- VistaGen Therapeutics, MindMed, Sumitomo Pharma America, Inc., Otsuka Pharmaceutical Co., Ltd, Sunovion Pharmaceuticals Inc., Cybin IRL Limited, Engrail Therapeutics Inc., Bionomics Limited, Receptor Life Sciences, MannKind Corporation, and others
• Generalized Anxiety Disorder Pipeline Therapies- MM-120, PH94B, Vilazodone (Viibryd), Intuniv (Guanfacine), BNC210, and others.
• Generalized Anxiety Disorder Market Dynamics: Generalized Anxiety Disorder Market Drivers and Barriers

Discover more about Generalized Anxiety Disorder Drugs in development @ Generalized Anxiety Disorder Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Generalized Anxiety Disorder (GAD) Market Overview at a Glance
4. Epidemiology and Market Methodology of GAD
5. Executive Summary of Generalized Anxiety Disorder (GAD)
6. Key Events
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey of GAD
10. Emerging Therapies
11. GAD: Market Analysis
12. Key Opinion Leaders' Views
13. SWOT Analysis
14. Unmet Needs
15. Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer

List of Top Selling Market Research Reports in 2025

Biopsy devices market- https://www.delveinsight.com/report-store/biopsy-devices-market
Diabetic wound market - https://www.delveinsight.com/report-store/diabetic-wounds-market
Joint reconstruction devices market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Heart failure market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive airway pressure device market - https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/report-store/intraocular-lens-market
Uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
Attention deficit hyperactivity disorder adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
Lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.